An internationally generalizable risk index for mortality after one year of antiretroviral therapy. - Wikidata - thesis-toulmin - TriplyDB

An internationally generalizable risk index for mortality after one year of antiretroviral therapy.

An internationally generalizable risk index for mortality after one year of antiretroviral therapy.

http://www.wikidata.org/entity/Q34813110

about

The end of AIDS: HIV infection as a chronic disease The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system.A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy.Utilizing patient data from the veterans administration electronic health record to support web-based clinical decision support: informatics challenges and issues from three clinical domains.Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions An adapted frailty-related phenotype and the VACS index as predictors of hospitalization and mortality in HIV-infected and uninfected individuals.Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations.The Impact of Marijuana Use on the Successful Aging of HIV-Infected Adults Weight change after antiretroviral therapy and mortality.Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy.Quality of HIV Care and Mortality Rates in HIV-Infected Patients.Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics.Number of Drinks to "Feel a Buzz" by HIV Status and Viral Load in Men Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men.Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality.Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?Management of human immunodeficiency virus infection in advanced age.Sex disparities in overall burden of disease among HIV-infected individuals in the Veterans Affairs healthcare system The next therapeutic challenge in HIV: polypharmacy.Association of the veterans aging cohort study index with exercise capacity in HIV-infected adults.Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumonia The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment.Frailty in people aging with human immunodeficiency virus (HIV) infection.The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): Protocol for Three Parallel Multi-Site Stepped Care Effectiveness Studies for Unhealthy Alcohol Use in HIV-Positive Patients.HIV and ageing: improving quantity and quality of life.Assessment of geriatric syndromes and physical function in people living with HIV.Prevalence and Predictors of Hospitalizations Among HIV-Infected and At-Risk HIV-Uninfected Women.No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).Direct and Indirect Effects of Heavy Alcohol Use on Clinical Outcomes in a Longitudinal Study of HIV Patients on ART.The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men.Long-term alcohol use patterns and HIV disease severity.

P2860

Q28300749-27C6A1D9-07D8-4D58-8148-0A29F9C41268 Q28541478-8B2CF482-EDD0-4C36-A8E2-3BC53A3639D8 Q28553516-C0589DB9-0925-43B9-9A83-338E98E2CE59 Q30894245-28B4A13C-C676-4E36-A19E-31528B8C9DDE Q33632714-AA96A089-E6FE-4C61-811B-F2D113728613 Q33816061-0DEDDC41-8648-4DE1-8888-EA7988E70980 Q33881303-0DF41583-3242-4F40-9396-A28EEA217C37 Q33919272-9EF59CB0-511F-4F99-A298-EE6D0333779F Q33980117-EB31B2E2-34CA-4460-ACDB-9AFA184641E2 Q34421879-8EE915A7-CD0F-4DF3-AA49-8F59A3BCE702 Q35036409-22372DF2-C480-4AD9-B303-06D12A2837D8 Q35049714-9C460A94-50AB-4FBF-9A47-DD1096D44C0A Q35656027-FD6FC4F1-BDD1-44C7-A3A6-DAC0E99977D1 Q35974655-90E1FEAF-69F2-4885-B642-4DA276EC8B30 Q36349654-8450EC24-2478-44EF-BC3B-ACC835637070 Q36402457-80ED5B56-5629-4372-9E05-7D802939051E Q36457683-077EA219-31F5-46A5-A394-09ABEFFF2D4A Q36658106-F1C48583-AA3E-4B6A-B061-8A33003D396D Q36689488-AD22C01E-AD63-4472-AA10-0838E2B353D0 Q36747893-DF6BCCDA-34D5-496F-8124-2FB720AE319F Q36765204-05B9FECE-A2D5-445F-A621-E512006449F8 Q36808952-B9020A7D-8F5C-41B9-BD19-E7C53D4E9655 Q36901589-CDC5E732-2A7E-477A-BA47-9836BE3AA14B Q36933984-6B75C814-3EFF-4A0F-9C1D-98DF0D7687C6 Q36962380-029F4C3D-0587-47F4-84E8-104B55A4A8F8 Q37025385-03A7A6F8-F4BE-4414-B4A5-9E768A5F7C45 Q37111462-C28DAFF8-27C8-4379-B501-C14E3C0515BE Q37216438-2BAA10C3-9D97-434B-8E69-CBDA763F925A Q37240889-74585E76-416F-4C33-92F6-AD97391CBECF Q37533136-26F8EA36-DC8C-4125-8789-F69887322FB4 Q38218045-D2A7E766-F74C-4E55-9797-F70AE42B849A Q38791854-69F35094-7BC3-4853-AF02-6479E44C4FA6 Q38883328-1415C79A-8E64-42A4-B346-C150C25CD01E Q38974942-EBBCDFB9-F9C4-4A04-BBC0-AA0D42FD5C1E Q39077764-53C89423-0D3B-4085-A065-7C34AC14C0EA Q39213852-D8271E79-B13D-46DD-97E9-CFC7758F73F3 Q39620568-28E634A5-5822-4978-99D1-D0FE2EFC94B3 Q39760836-E217038A-8D78-4857-A162-6C8C2306E235 Q40049988-D9F3D149-FF51-4CFC-9D8E-B10C93354FE2 Q40206466-1C2B0CA9-9B8E-4DE0-B722-DFD09D47EC6B

P2860

An internationally generalizable risk index for mortality after one year of antiretroviral therapy.

http://www.wikidata.org/entity/Q34813110

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

An internationally generalizab ...... ear of antiretroviral therapy.

@ast

An internationally generalizab ...... ear of antiretroviral therapy.

@en

An internationally generalizab ...... ear of antiretroviral therapy.

@nl

type

label

An internationally generalizab ...... ear of antiretroviral therapy.

@ast

An internationally generalizab ...... ear of antiretroviral therapy.

@en

An internationally generalizab ...... ear of antiretroviral therapy.

@nl

prefLabel

An internationally generalizab ...... ear of antiretroviral therapy.

@ast

An internationally generalizab ...... ear of antiretroviral therapy.

@en

An internationally generalizab ...... ear of antiretroviral therapy.

@nl

P1433

Q34813110-C0F916F3-4DB0-406E-990B-F3C5DF633FFE

P1476

Q34813110-F496F291-C53A-41E4-BCC9-3A0056A17FA5

P2093

Q34813110-5B168123-F9A1-4748-BDA3-B013026F8946

Q34813110-65DDC773-0D71-4E04-B445-6EBAA303D573

Q34813110-6D9CE311-7BCD-4287-9239-101EA661571D

Q34813110-889BB98F-0F93-437F-9110-793EFA0D4315

Q34813110-9B0844DC-94A0-4EF8-81B1-792DF1A7E4F8

Q34813110-C5160059-B258-4DD6-80B1-4B7D40140D29

Q34813110-CA78878C-FD0F-42D1-846F-CE473E13A170

Q34813110-CC044977-6240-4AA9-AFF6-CDA35F8E8D72

Q34813110-D2410F0D-DCF1-40F8-B910-A228B01C64AE

Q34813110-D9FC062A-4D26-4198-839E-4694F816A0BC

P2860

Q34813110-11D1A393-5875-4300-BBC1-148C60424F39

Q34813110-1235FB43-3DE2-428A-AA52-49A09CF01AC4

Q34813110-18EEF675-677D-4518-AB9D-C106A4F8E0BB

Q34813110-19875D29-6399-446E-81C4-3A8264340241

Q34813110-1C682B3F-5C9F-4E89-8DCA-D91722739CD8

Q34813110-38B5F91A-1359-4FAB-8293-CFC68F9A38DA

Q34813110-4A3B1886-9E9A-44EA-B867-53EA8A74ED3C

Q34813110-4CC6CFA3-F3E8-41D1-B0EA-05F6E89F71BA

Q34813110-61AAAC36-913A-4739-B406-1E74C5BB141D

Q34813110-704FC3DB-CE80-4023-8681-DD509FEE0630

P304

Q34813110-EFE9E6DD-1ADA-465B-907F-2EFA933C7755

P31

Q34813110-ADAB585C-0665-4124-99B7-66E6D4EA040C

P356

Q34813110-3A0418D5-100B-492B-835F-E5A58071F475

P407

Q34813110-18401F66-A967-430E-8360-6E7764B130C8

P433

Q34813110-ADA8F953-AE62-4D89-A2E0-0416F15106BB

P478

Q34813110-892E5779-1678-460B-A8E3-2AFB8F5165A7

P50

Q34813110-7AE54D08-829C-4486-817E-8CBA38A7091D

Q34813110-CA4F5706-4F6D-4577-BFDE-A4918F15A9FB

P577

Q34813110-54EC4E93-95F5-4E59-93AE-F47D24003C7D

P698

Q34813110-88A277C3-FABD-4A3E-8248-DE5FF387DB3C

P921

Q34813110-503C7F70-8F38-4C0D-8747-44F31EF9E426

P932

Q34813110-F7124FAF-3D5A-4E7F-BEC7-CF14C1D1FD49

P356

QAD.0B013E32835B8C7F

P1433

P1476

An internationally generalizab ...... year of antiretroviral therapy

@en

P2093

Amanda Mocroft

http://www.w3.org/2001/XMLSchema#string

Amy C Justice

http://www.w3.org/2001/XMLSchema#string

Fabrice Bonnet

http://www.w3.org/2001/XMLSchema#string

Fiona C Lampe

http://www.w3.org/2001/XMLSchema#string

Heidi M Crane

http://www.w3.org/2001/XMLSchema#string

Heiner C Bucher

http://www.w3.org/2001/XMLSchema#string

Jacob Nattermann

http://www.w3.org/2001/XMLSchema#string

Janet P Tate

http://www.w3.org/2001/XMLSchema#string

Mari M Kitahata

http://www.w3.org/2001/XMLSchema#string

Michael D Hughes

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Coronary Heart Disease Using Risk Factor Categories

The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?

Prognostic indices for older adults: a systematic review

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

CD4+ count-guided interruption of antiretroviral treatment

Presentation of multivariate data for clinical use: The Framingham Study risk score functions.

Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.

Assessing the generalizability of prognostic information.

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection

The continuing value of the Apgar score for the assessment of newborn infants.

P304

563-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32835B8C7F

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Sterne

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23095314

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4283204

http://www.w3.org/2001/XMLSchema#string